@article{e2adde40f062408c855d9595658c065c,
title = "Risk of male breast cancer after Hodgkin lymphoma",
abstract = "Female survivors of Hodgkin lymphoma (HL) treated with chest radiotherapy have a strongly increased risk of breast cancer (BC), but the treatment-specific BC risk in male survivors of HL has not been evaluated. We assessed BC risk in a cohort of 3077 male survivors of 5-year HL treated at age ≤51 years in 20 Dutch hospitals between 1965 and 2013. We estimated standardized incidence ratios (SIRs), absolute excess risks per 10 000 person-years, and cumulative BC incidences. After a 20-year median follow-up, we observed 8 cases of male with BC. Male survivors of HL experienced a 23-fold (95% confidence interval [CI], 10.1-46.0) increased BC risk compared with the general population, representing 1.6 (95% CI, 0.7-3.3) excess BC incidences per 10 000 person-years. The 20- and 40-year cumulative BC incidences after HL treatment were 0.1% (95% CI, 0.02-0.3) and 0.7% (95% CI, 0.3-1.4), respectively. Treatment with chest radiotherapy without alkylating chemotherapy yielded a strongly increased SIR (20.7; 95% CI, 2.5-74.8), which was not significantly different for chest radiotherapy and alkylating chemotherapy (41.1; 95% CI, 13.4-96.0). Males treated with chest radiotherapy and anthracyclines had an SIR of 48.1 (95% CI, 13.1-123.1). Two patients died from BC (median follow-up, 4.7 years). To ensure early diagnosis and treatment, clinicians should be alert to BC symptoms in male survivors of HL.",
author = "{de Vries}, Simone and Krul, {Inge M.} and Michael Schaapveld and Janus, {Cecile P. M.} and Rademakers, {Saskia E.} and Roesink, {Judith M.} and Nijziel, {Marten R.} and Bilgin, {Yavuz M.} and {BETER consortium} and {van Leeuwen}, {F. E.} and A. Nijdam and Aleman, {B. M. P.} and {de Boer}, {J. P.} and Janus, {C. P. M.} and Mutsaers, {P. G. N. J.} and C. So-Osman and Zijlstra, {J. M.} and Meijer, {O. W. M.} and Rademakers, {S. E.} and Krol, {A. D. G.} and Kersten, {M. J.} and Tonino, {S. H.} and M. Jalink and Dani{\"e}ls, {L. A.} and {van Spronsen}, {D. J.} and {van der Maazen}, {R. W. M.} and J. Loonen and Roesink, {J. M.} and R. Oostvogels and {de Weijer}, R. and D. Buter and {de Boer}, A. and Aarsman, {K. M.} and Oudbier, {C. W.} and Nijziel, {M. R.} and {van den Berg}, M. and K. Verschueren and M. Schippers and Boersma, {R. S.} and Issa, {D. E.} and Plattel, {W. J.} and Stedema, {F. G.} and Koene, {H. R.} and Raymakers, {E. R. P. M.} and E. Schimmel and {van Hezewijk}, M. and P. Bouma and K. Muller and C. Siemes and {van der Spek}, {J. M.} and S. Kuipers",
note = "Funding Information: This work was supported by the Dutch Cancer Society (NKI 2010-4720 ) (F.E.v.L.). Funding Information: The authors thank Rosemarie Wijnands for the data support at the Netherlands Cancer Institute. This work was supported by the Dutch Cancer Society (NKI 2010-4720) (F.E.v.L.). Contribution: S.d.V. I.M.K. B.M.P.A. and F.E.v.L. designed the study; C.P.M.J. S.E.R. J.M.R. M.R.N. Y.M.B. B.M.P.A. and the BETER consortium provided study patients; S.d.V. M.S. and F.E.v.L. collected and assembled data; S.d.V. I.M.K. M.S. B.M.P.A. and F.E.v.L. analyzed and interpreted data; S.d.V. I.M.K. and F.E.v.L. contributed to manuscript writing; and all authors approved the final manuscript. Publisher Copyright: {\textcopyright} 2023 The American Society of Hematology",
year = "2023",
month = aug,
day = "31",
doi = "https://doi.org/10.1182/blood.2023020940",
language = "English",
volume = "142",
pages = "806--811",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",
}